Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243763 · ClinicalTrials.gov registry record · Phase 1
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
A Phase 1 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00243763: Clinical Trial Phase 1 study, sponsored by Novartis.
NCT00243763 is a Phase 1 study that was terminated before completion, run by Novartis. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00243763, a Phase 1 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
Interventions
- DRUG TKI258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Phase | Phase 1 |
Why NCT00243763 stopped before completion
NCT00243763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which TKI258 is the first listed.
NCT00243763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00243763 about?
NCT00243763 is a clinical study titled "TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma". The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
What is the current status of trial NCT00243763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 64 participants.
What interventions are being tested in trial NCT00243763?
The interventions under investigation include: TKI258 (DRUG).
Who is sponsoring clinical trial NCT00243763?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00243763's enrollment target sits among peer trials
64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins